Annovis Bio

Historical price data

Annovis Bio is a Phase 3 neuroscience biotech developing buntanetap, an oral translational inhibitor designed to reduce multiple neurotoxic proteins (APP, tau, α-synuclein) to restore axonal transport and stop neuronal death. The company's strategy targets a common upstream mechanism in Alzheimer's and Parkinson's disease, differentiating it from monoclonal antibody competitors. With late-stage trials underway, Annovis aims to deliver a first-in-class, disease-modifying therapy for major neurodegenerative conditions with high unmet need.

A small-molecule translational inhibition platform targeting the Iron Responsive Element (IRE) to reduce the production of multiple neurotoxic proteins (APP, tau, α-synuclein) that drive neurodegeneration.

Competes against IV monoclonal antibodies in Alzheimer's (Eisai/Biogen, Lilly) and a growing field of disease-modifying candidates in Parkinson's. Differentiation hinges on buntanetap's oral dosing and upstream, multi-protein mechanism targeting a common pathological cascade.